Indivior (INDV) Competitors

GBX 1,340
-7.88 (-0.58%)
(As of 07:36 AM ET)

INDV vs. HCM, HIK, GNS, SPI, ONT, CRW, UPR, PRTC, CTEC, and BMK

Should you be buying Indivior stock or one of its competitors? The main competitors of Indivior include HUTCHMED (HCM), Hikma Pharmaceuticals (HIK), Genus (GNS), Spire Healthcare Group (SPI), Oxford Nanopore Technologies (ONT), Craneware (CRW), Uniphar (UPR), PureTech Health (PRTC), ConvaTec Group (CTEC), and Benchmark (BMK). These companies are all part of the "medical" sector.

Indivior vs.

HUTCHMED (LON:HCM) and Indivior (LON:INDV) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

HUTCHMED has a net margin of 12.03% compared to HUTCHMED's net margin of 0.44%. Indivior's return on equity of 14.65% beat HUTCHMED's return on equity.

Company Net Margins Return on Equity Return on Assets
HUTCHMED12.03% 14.65% 0.99%
Indivior 0.44%12.20%9.94%

34.3% of HUTCHMED shares are held by institutional investors. Comparatively, 85.6% of Indivior shares are held by institutional investors. 42.9% of HUTCHMED shares are held by insiders. Comparatively, 3.3% of Indivior shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

HUTCHMED has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Indivior has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500.

Indivior received 360 more outperform votes than HUTCHMED when rated by MarketBeat users. Likewise, 80.35% of users gave Indivior an outperform vote while only 78.40% of users gave HUTCHMED an outperform vote.

CompanyUnderperformOutperform
HUTCHMEDOutperform Votes
196
78.40%
Underperform Votes
54
21.60%
IndiviorOutperform Votes
556
80.35%
Underperform Votes
136
19.65%

Indivior has a consensus price target of GBX 2,515, suggesting a potential upside of 87.28%. Given HUTCHMED's higher possible upside, analysts clearly believe Indivior is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HUTCHMED
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Indivior
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

HUTCHMED has higher earnings, but lower revenue than Indivior. HUTCHMED is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HUTCHMED£838M3.26£100.78M£0.093,555.56
Indivior£1.12B1.62£5M£0.0344,666.67

In the previous week, HUTCHMED had 2 more articles in the media than Indivior. MarketBeat recorded 2 mentions for HUTCHMED and 0 mentions for Indivior. Indivior's average media sentiment score of 0.17 beat HUTCHMED's score of 0.00 indicating that HUTCHMED is being referred to more favorably in the media.

Company Overall Sentiment
HUTCHMED Neutral
Indivior Neutral

Summary

HUTCHMED beats Indivior on 9 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INDV vs. The Competition

MetricIndiviorDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£1.81B£1.21B£4.89B£1.44B
Dividend Yield4.48%2.99%44.82%11.84%
P/E Ratio44,666.67438.68115.971,681.39
Price / Sales1.627,765.842,445.06257,702.60
Price / Cash2.689.9432.5832.84
Price / Book191.436.835.132.71
Net Income£5M£143.33M£100.62M£165.85M
7 Day Performance-6.82%1,722.14%117.52%1.20%
1 Month Performance-11.49%1,854.56%124.72%5.01%
1 Year Performance-11.78%2,041.21%134.78%10.38%

Indivior Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HCM
HUTCHMED
0 of 5 stars
GBX 344
-1.7%
N/A+57.3%£2.94B£838M3,440.001,988
HIK
Hikma Pharmaceuticals
0.842 of 5 stars
GBX 2,002
-0.5%
GBX 2,068.75
+3.3%
+8.3%£4.44B£2.88B2,944.129,100
GNS
Genus
0 of 5 stars
GBX 1,860
-0.4%
GBX 4,500
+141.9%
-25.8%£1.23B£673.10M3,647.063,500Gap Down
High Trading Volume
SPI
Spire Healthcare Group
0.762 of 5 stars
GBX 259.50
+2.4%
GBX 302.25
+16.5%
+8.2%£1.05B£1.36B3,707.1412,787
ONT
Oxford Nanopore Technologies
2.3955 of 5 stars
GBX 111.20
+1.5%
GBX 303.75
+173.2%
-56.2%£959.20M£169.67M-585.261,238Positive News
CRW
Craneware
1.1667 of 5 stars
GBX 2,230
+0.9%
GBX 2,600
+16.6%
+45.1%£787.86M£180.56M10,619.05734
UPR
Uniphar
0 of 5 stars
GBX 224
flat
N/A-20.9%£611.57M£2.55B1,600.003,000
PRTC
PureTech Health
0 of 5 stars
GBX 222.50
-0.2%
N/A+6.8%£601.66M£3.33M-1,171.05300
CTEC
ConvaTec Group
1.0269 of 5 stars
GBX 262.20
+0.8%
GBX 307.17
+17.1%
+11.1%£5.38B£2.14B5,244.0010,136
BMK
Benchmark
0 of 5 stars
GBX 44.50
+4.0%
N/A+11.9%£329.16M£155.53M-1,483.33823

Related Companies and Tools

This page (LON:INDV) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners